Argenx Se (ARGX) Inventory (2020 - 2026)
Argenx Se's (ARGX) quarterly Inventory came in at $371.0 million in Q2 2026, down 99.89% YoY from $340.6 billion in Q2 2025, and down 21.73% on a QoQ basis from $474.0 million in Q4 2025.
Argenx Se (ARGX) Inventory (2020 - 2026) Analysis & Trends
Argenx Se (ARGX) has 7 years of Inventory data on file, last reported at $371.0 million in Q2 2026.
- Quarterly Inventory fell 99.89% year-over-year to $371.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $371.0 million (down 99.89% YoY) and the FY2025 annual result came in at $474.0 million, up 16.4% from the prior year.
- Inventory declined to $371.0 million in Q2 2026, from $474.0 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $340.6 billion in Q2 2025 to a low of $135.7 million in Q2 2022.
- A 5-year average of $38.1 billion and a median of $326.5 million in 2024 frame the typical range for Inventory.
- Annual changes were most pronounced in 2025 — Inventory surged 104237.74% — and 2026, when it sank 99.89%.
- Tracing ARGX's Inventory over 5 years: stood at $228.4 million in 2022, then soared by 36.0% to $310.6 million in 2023, then surged by 31.13% to $407.2 million in 2024, then advanced by 16.4% to $474.0 million in 2025, then decreased by 21.73% to $371.0 million in 2026.
- The last three Inventory figures came in at $371.0 million (Q2 2026), $474.0 million (Q4 2025), and $340.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 371.00 Mn |
| Dec 31, 2025 | 474.00 Mn |
| Jun 30, 2025 | 340.62 Bn |
| Dec 31, 2024 | 407.23 Mn |
| Jun 30, 2024 | 326.46 Mn |
| Dec 31, 2023 | 310.55 Mn |
| Jun 30, 2023 | 201.11 Mn |
| Dec 31, 2022 | 228.35 Mn |
| Jun 30, 2022 | 135.71 Mn |
| Dec 31, 2021 | 109.08 Mn |
| Jun 30, 2021 | 59.22 Mn |
| Dec 31, 2020 | 24.48 Mn |
| Jun 30, 2020 | 5.48 Mn |